SCHEMBL1198762

SCHEMBL1198762

COc1ccc(CNc2cccnc2CN)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
CYP1A2 P05177 13/20 0.49
CYP3A4 P08684 13/20 0.49
CYP2D6 P10635 13/20 0.49
CYP2C19 P33261 12/20 0.49
TSHR P16473 10/20 0.49
CLK4 Q9HAZ1 9/20 0.49
LMNA P02545 7/20 0.49
USP2 O75604 5/20 0.49
HSD17B10 Q99714 4/20 0.49
CYP2C9 P11712 4/20 0.49
ALOX15 P16050 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPK1 P28482 6/20 0.47
ALDH1A1 P00352 4/20 0.47
GLA P06280 1/20 0.47
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL4761888 0.96 KDM4C (0.47) APLNRKDM4CCYP1A2CYP3A4CYP2D6
SCHEMBL1197180 0.81 CYP1A2 (0.55) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL319266 0.80 APLNR (0.63) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL1198126 0.80 CYP1A2 (0.53) APLNRKDM4CCYP1A2CYP3A4CYP2D6
SCHEMBL29581979 0.78 CYP1A2 (0.56) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL13273549 0.77 CYP1A2 (0.52) APLNRKDM4CCYP1A2CYP3A4CYP2D6
SCHEMBL16109009 0.76 L3MBTL1 (0.74) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL29669157 0.76 L3MBTL1 (0.74) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30080224 0.75 CYP1A2 (0.56) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL1198634 0.74 KDM4C (0.49) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2039694-B1 CGRP receptor antagonists MERCK SHARP & DOHME (US) 2014-03-26 EP disclosed
US-7893052-B2 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2011-02-22 US disclosed
US-20100298303-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-11-25 US disclosed
US-7772224-B2 Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches MERCK SHARP & DOHME CORP. (US) 2010-08-10 US disclosed
US-7745427-B2 CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2010-06-29 US disclosed
EP-1641423-B1 BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2010-03-17 EP disclosed
US-20090192139-A1 Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches MERCK SHARP & DOHME LLC 2009-07-30 US disclosed
US-7534784-B2 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide MERCK + CO., INC. (US) 2009-05-19 US disclosed
EP-2039694-A1 CGRP receptor antagonists Merck & Co., Inc. (US) 2009-03-25 EP disclosed
US-7476665-B2 Benzodiazepine CGRP receptor antagonists MERCK & CO., INC. (US) 2009-01-13 US disclosed
US-20080280857-A1 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2008-11-13 US disclosed
US-20080090806-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-04-17 US disclosed
US-20070225272-A1 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-09-27 US disclosed
US-7235545-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2007-06-26 US disclosed
US-20070111204-A1 Methods for detecting nucleic acid variations TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE 2007-05-17 US disclosed
US-20060135511-A1 Benzodiazepine cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-06-22 US disclosed
EP-1638969-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2006-03-29 EP disclosed
US-6953790-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2005-10-11 US disclosed
US-20040229861-A1 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2004-11-18 US disclosed
WO-2004092166-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135511-A1 Benzodiazepine cgrp receptor antagonists NPY1R, NPY2R, CCKBR APLNR 981/4885KDM4C 2530/4885CYP1A2 793/4885
US-20080090806-A1 Cgrp Receptor Antagonists CCKBR, BDKRB1, BDKRB2 APLNR 411/4885KDM4C 3502/4885CYP1A2 2161/4885
US-20040229861-A1 CGRP receptor antagonists CCKBR, CCKAR, CALCRL APLNR 461/4885KDM4C 3908/4885CYP1A2 1950/4885
US-20090192139-A1 Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches CALCRL, CALCB, CALCR APLNR 417/4885KDM4C 1955/4885CYP1A2 1871/4885
US-20070111204-A1 Methods for detecting nucleic acid variations POLN, LIG4, NCL APLNR 1100/4885KDM4C 1846/4885CYP1A2 4159/4885
US-20100298303-A1 CGRP RECEPTOR ANTAGONISTS CCKBR, BDKRB1, BDKRB2 APLNR 407/4885KDM4C 3619/4885CYP1A2 1991/4885
US-20070225272-A1 CGRP receptor antagonists CCKBR, BDKRB1, BDKRB2 APLNR 407/4885KDM4C 3619/4885CYP1A2 1991/4885
US-20080280857-A1 CGRP receptor antagonists CCKBR, BDKRB1, BDKRB2 APLNR 407/4885KDM4C 3619/4885CYP1A2 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.